EP.233

THE FORCE™ PLATFORM ACHIEVES DURABLE KNOCKDOWN OF TOXIC HUMAN NUCLEAR *DMPK* RNA AND CORRECTION OF SPLICING IN THE hTfR1/DMSXL MOUSE MODEL

S ZANOTTI, T PICARIELLO, J CUI, N HSIA, T WEEDEN, RJ RUSSO, L SCHLAEFKE, A CHANG, M YAO, A WEN, S HILDEBRAND, J NAJIM, Q QIU, B QUINN, M QATANANI, J W DAVIS II, R SUBRAMANIAN, O BESKROVNAYA

Dyne Therapeutics Inc, Waltham, MA, USA

BACKGROUND

- Myotonic dystrophy type 1 (DM1) is a rare, debilitating, genetic, progressive neuromuscular disease caused by expansion of CUG repeats in the 3' untranslated region of the dystrophia myotonica protein kinase (*DMPK*) RNA[1]
  - *DMPK* transcripts with CUG repeats expansion are trapped in the nucleus and bind to muscleblind-like (MBNL) splicing factors, sequestering them in toxic nuclear foci,[2] ultimately resulting in splicing defects[3]
  - Currently, there are no approved therapies for DM1[4]
- DYNE-101 was designed to target the *DMPK* RNA for RNAse-H-mediated degradation by an antisense oligonucleotide (ASO). The ASO is joined by a clinically validated valine-citrulline linker to an antigen-binding fragment (Fab) antibody that targets the human transferrin receptor 1 (hTfR1), which is highly expressed on muscle
- Using an innovative DM1 mouse model (hTfR1/DMSXL hemizygotes), we report for the first time:
  - Direct *in vivo* evidence that human mutant *DMPK* RNA is trapped in the nucleus of hTfR1/DMSXL muscle
  - DYNE-101 acts in the nucleus to degrade human toxic *DMPK* RNA
- Using hTfR1/DMSXL homozygous mice that develop spliceopathy, we demonstrate that DYNE-101:
  - Effectively reduces human toxic *DMPK* KD, degrades foci, and corrects spliceopathy in the heart
  - Corrects splicing defects across multiple skeletal muscles
- DYNE-101 was well tolerated in non-GLP toxicology study in non human primates (NHP)

METHODS

- hTfR1/DMSXL mice express the hTfR1 and a human *DMPK* gene with > 1000 CTG repeats (DMSXL)[2] that is representative of a severe DM1 phenotype
- Homozygous hTfR1/DMSXL mice are a novel model that carries 2 copies of the human *DMPK* gene yielding higher *DMPK* expression compared with hemizygous DMSXL and have a DM1 splicing phenotype
- Fractionation studies were conducted in hTfR1/DMSXL hemizygous mice treated on day 0 with 10 mg/kg DYNE-101 or with phosphate buffered saline (PBS) and analyzed on day 28
- *DMPK* RNA, foci, and splicing were assessed in hTfR1/DMSXL homozygous mice treated on day 0 and day 7 with 10 mg/kg DYNE-101 or with PBS and analyzed on day 28
- Non-GLP dose-range finding toxicity studies for DYNE-101 were performed in male Asian cynomolgus monkeys

RESULTS

Figure 1. hTfR1/DMSXL Mice are a PK/PD Model, and NHP are a PK and Tolerability Model



Figure 2. Toxic Human *DMPK* is Trapped in Nuclei of Skeletal Muscle of hTfR1/DMSXL Hemizygous Mice



DMPK RNA expression by qRT-PCR in nuclear fractions from hTfR1/DMSXL gastrocnemius confirms nuclear localization. *Malat1* serves as a nuclear RNA marker. Data are mean ± SD; n = 2.

Figure 3. DYNE-101 Leads to Robust KD of Toxic Human *DMPK* in Nuclei From Gastrocnemius of hTfR1/DMSXL Hemizygous Mice



DMPK KD measured by qRT-PCR in nuclear fractions. Data are mean ± SD; n = 2.

Figure 4. DYNE-101 Delivers Sustained Toxic Human *DMPK* RNA KD and Foci Reduction, Leading to Splicing Correction in the Heart of hTfR1/DMSXL Homozygous Mice



DMPK KD measured by qRT-PCR, representative images from *in situ* hybridization chain reaction in heart tissues with quantification on FIJI software, composite splicing index of *Ldb3* exon (E)11, *Mbnl2* exon E6, and *Nfix* E7 mis-splicing measured by qRT-PCR. Data are mean ± SD; n = 7; **P* < .05; *****P* < .0001, by *t*-test.

Figure 5. DYNE-101 Delivers Sustained Toxic Human *DMPK* RNA KD, Leading to Splicing Correction in Skeletal Muscles of hTfR1/DMSXL Homozygous Mice



DMPK KD measured by qRT-PCR; composite splicing index[5] of *Bin1* E11, *Insr* E11, *Ldb3* E11, *Mbnl2* E5, *Mbnl2* E6, *Nfix* E7, and *Ttn* E313 mis-splicing measured by qRT-PCR. Data are mean ± SD; n = 4–7; *P* < .0001, by *t*-test.

DYNE-101 WAS WELL TOLERATED IN NHP NON-GLP TOXICOLOGY DOSE-RANGE FINDING STUDY

- No adverse findings in cynomolgus monkeys after repeat ascending doses of DYNE-101
- No effects on body weight with no clinical signs of toxicity
- No test article-related macroscopic observations or organ weight changes
- No effect on kidney and liver function

CONCLUSIONS

- These data demonstrate that DYNE-101:
  - Reduces toxic human nuclear *DMPK* RNA and foci and corrects splicing defects in the hTfR1/DMSXL model of DM1
  - Is well tolerated in cynomolgus monkeys after repeat dosing
- These results support further development of DYNE-101, including a planned clinical study

REFERENCES

1. Thornton CA. *Neurol Clin*. 2014;32:705–719.
2. Huguet A, et al. *PLoS Genet*. 2012;8:e1003043. doi:10.1371/journal.pgen.1003043
3. Nakamori M, et al. *Ann Neurol*. 2013;74:862–872.
4. Thornton CA, et al. *Curr Opin Genet Dev*. 2017;44:135–140.
5. Tanner MK, et al. *Nucleic Acids Res*. 2021;49:2240–2254.

DISCLOSURE INFORMATION

All authors are employees or advisors of Dyne Therapeutics Inc, and may hold Dyne stock and/or stock options

ACKNOWLEDGMENT

We thank Dr. Geneviève Gourdon for providing the DMSXL mice